# agilon health, inc. (AGL) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-04  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/agl/thesis · /memo/agl

## Financial Snapshot

---
source: coverage-next-full
ticker: AGL
company: agilon health, inc.
step: 04
title: Financial Quality & Adversarial Sweep
created: 2026-06-04
---

### Step 04 — Financial Quality: agilon health, inc. (AGL)

#### 1. Income Statement Quality Assessment

##### Revenue Recognition
- Revenue recognized on a gross basis (full capitation PMPM × members) per ASC 606
- Capitation revenue is monthly, straight-line; no material timing distortions
- Risk-adjustment settlements are estimated and trued up quarterly; FY2024 and FY2025 saw material adverse true-ups ($37M and $48M respectively) — this is NOT a recognition distortion, it reflects the genuine actuarial uncertainty in CMS risk-adjustment methodology [S2]
- **Quality: CLEAN** on recognition method; elevated estimation risk on risk-adjustment true-ups is disclosed prominently

##### Medical Cost Accruals
- agilon records IBNR (Incurred But Not Reported) claims liability based on actuarial estimates
- IBNR balance: FY2024 $~460M → FY2025 $~502M
- Reserve development (adverse vs. favorable) has been a persistent negative in FY2024–FY2025
- **Quality: WATCH** — IBNR adequacy is the most critical financial reporting risk; management has a track record of underestimating medical costs in recent years

##### Non-GAAP Adjustments
- Adjusted EBITDA excludes: SBC (~$50–55M/yr), D&A (~$35M/yr), restructuring charges (~$15M in FY2025), legal/investigation costs
- SBC is large relative to the company's scale (~$50M on a ~$5.9B revenue base but very large relative to the ~-$57M medical margin in FY2025)
- **Quality: MODERATE CONCERN** — Adjusted EBITDA in FY2025 ($-230M) is much better than GAAP loss ($-356M); the adjustments are standard but SBC is not trivial

#### 2. Balance Sheet Quality

| Metric | FY2024 | FY2025 | Assessment |
|--------|--------|--------|-----------|
| Cash & equivalents | $259M | $182M | Declining rapidly; key liquidity monitor |
| Total debt | $50M | $50M | Minimal; $50M revolving credit facility (undrawn as of Q1 2026) |
| Goodwill + intangibles | ~$125M | ~$120M | Legacy; modest impairment risk |
| Claims payable (IBNR) | ~$460M | ~$502M | Largest liability; actuarial risk embedded |
| Total equity | ~$378M | ~$22M | Nearly depleted by cumulative losses |

**Capital structure note:** AGL is effectively equity-funded with minimal traditional debt. However, the claims payable (IBNR) represents a contingent liability that could require cash payment materially in excess of estimates if adverse development continues. The equity base is nearly zero; another year of FY2025-magnitude losses would require external capital. The FY2026 turnaround is therefore existentially important. [S1][S2]

**Reverse stock split (March 31, 2026, 1:25):** Executed to maintain NYSE listing compliance — the stock had fallen below the $1.00 minimum bid price. This is a material signal of the severity of the FY2025 crisis, not just cosmetic. [S6]

#### 3. Cash Flow Quality

| Metric | FY2023 | FY2024 | FY2025 |
|--------|--------|--------|--------|
| Operating Cash Flow | ($80M) | ($57M) | ($187M) |
| Capex | ($16M) | ($21M) | ($18M) |
| Free Cash Flow | ($96M) | ($78M) | ($205M) |

FY2025 FCF of -$205M represents the worst cash burn year. Management guided FY2026 cash burn to dramatically narrow given EBITDA inflection. [S1]

**Working capital note:** Capitation payments are received monthly in advance; medical costs are paid with a lag. This creates a structural working capital benefit in growth phases but can reverse during membership declines as run-out claims must still be paid on departing members.

#### 4. SBC Analysis

| Year | SBC | SBC / Revenue | SBC / Medical Margin |
|------|-----|-------------|---------------------|
| FY2022 | $64M | 1.9% | 39% |
| FY2023 | $59M | 1.2% | 20% |
| FY2024 | $55M | 0.9% | 27% |
| FY2025 | $50M | 0.8% | N/M (negative MM) |

SBC as % of revenue is low, but as % of medical margin it is extremely high in FY2024–2025. SBC is a significant cost to equity holders even if excluded from Adj. EBITDA. [S1]

#### 5. Adversarial Research Sweep

##### 5a. Securities Class Action (Active)

**Filed:** December 31, 2025
**Class period:** February 2, 2024 – August 4, 2025
**Allegations:** The complaint alleges AGL misled investors about the sustainability of its medical margin and the severity of deteriorating medical cost trends during the class period. Specifically, plaintiffs allege AGL knew or should have known that: (1) Medicare Advantage medical costs were trending significantly above estimates; (2) risk-adjustment true-ups would be materially adverse; (3) Part D IRA changes would materially impair profitability — and failed to timely disclose this risk. The CEO departure on August 4, 2025 (simultaneous with guidance suspension) serves as the alleged "corrective disclosure" event.

**Assessment:** The allegations are legally plausible — the abruptness of the FY2025 guidance suspension and CEO departure is facially unusual. However, AGL's core defense is that medical cost deterioration in MA was industry-wide (HUM, CVS, ELV all experienced elevated MA costs in 2024–2025) and was not predictable with certainty. Securities class actions in healthcare frequently settle; material cash outflow is possible but the timeframe is typically 2–4 years. [S6]

##### 5b. Short Seller History

No major organized short-seller campaign against AGL was identified. Short interest peaked pre-reverse-split at ~26.7M equivalent shares (~6% of post-split float equivalent) and had substantially compressed by May 2026 to ~640K shares (0.8 days to cover). The compression occurred as FY2026 early results recovered. No SEC investigation publicly disclosed as of research date. [S5]

##### 5c. Accounting Red Flags Assessment

| Risk Area | Finding | Severity |
|-----------|---------|---------|
| IBNR reserve adequacy | Consistent adverse development FY2024–2025; this is genuine actuarial uncertainty, not manipulation evidence | MEDIUM |
| SBC exclusion from Adj. EBITDA | Standard practice; disclosed; but large relative to economics | LOW-MEDIUM |
| Gross revenue recognition | Per ASC 606; appropriate for the RBE structure | LOW |
| Related party transactions | No material related-party transactions identified | LOW |
| Audit firm | Deloitte (large national firm) | LOW |
| Going concern | Not disclosed in FY2025 10-K; balance sheet stressed but management believes FY2026 guidance provides sufficient liquidity | LOW-MEDIUM |

##### 5d. Management Credibility Events

| Event | Date | Implication |
|-------|------|-------------|
| CEO Steven Sell resignation | Aug 4, 2025 | Simultaneous with guidance suspension — raises credibility questions about FY2024–2025 disclosures |
| Guidance suspension Aug 2025 | Aug 4, 2025 | Only the second time in company history guidance was suspended |
| FY2025 medical margin -$57M vs. original guidance of +$175M+ | Dec 2025 | ~$232M guidance miss — material |
| Reverse stock split | Mar 2026 | Avoided delisting; signal of severity |
| New CEO O'Rourke joined | May 2026 | VBC veteran; credibility upgrade vs. crisis period |

**Net credibility assessment:** The prior management team's credibility is compromised by the FY2025 earnings miss severity. New CEO O'Rourke's first full guidance cycle (FY2026) will be a critical test. Q1 2026 beat ($149M medical margin vs. ~$120M implied guidance) is a positive first data point. [S6]

#### 6. Key Financial Quality Adjustments for Modeling

1. **IBNR adequacy:** Add 5–10% IBNR development risk haircut to medical margin estimates in scenarios
2. **SBC:** Treat as real economic cost in bear/base case analysis (reduces true profitability by ~$50M/yr)
3. **Reverse split adjustment:** All per-share historical data post-split is retroactively adjusted (÷25); verify all per-share figures from databases use the adjusted basis
4. **Part D tail:** FY2026 contracts explicitly reprice Part D; the risk should diminish, but one more year of adverse development is a monitoring item

#### 7. Source Index

| ID | Source |
|----|--------|
| S1 | SEC EDGAR XBRL — AGL company facts |
| S2 | AGL 10-K FY2024 |
| S5 | Analyst consensus data |
| S6 | AGL_financials/other/business_deep_research.md |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/AGL/fundamental

## Navigation

- Overview: /stocks/agl
- Financials (this page): /stocks/agl/financials
- Thesis: /stocks/agl/thesis
- Investment Memo: /memo/agl
- Coverage universe: /stocks